Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 7.30% and Operating profit at -28.69% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
3
With ROE of 3.56%, it has a very expensive valuation with a 2.28 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,316 Million (Mid Cap)
64.00
NA
0.00%
-0.01
4.39%
2.79
Revenue and Profits:
Net Sales:
112 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.75%
0%
-19.75%
6 Months
28.07%
0%
28.07%
1 Year
53.1%
0%
53.1%
2 Years
512.92%
0%
512.92%
3 Years
274.25%
0%
274.25%
4 Years
195.1%
0%
195.1%
5 Years
87.32%
0%
87.32%
HOB Biotech Group Corp. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.30%
EBIT Growth (5y)
-28.69%
EBIT to Interest (avg)
32.88
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.44
Tax Ratio
11.66%
Dividend Payout Ratio
50.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.39%
ROE (avg)
6.28%
Valuation key factors
Factor
Value
P/E Ratio
64
Industry P/E
Price to Book Value
2.28
EV to EBIT
89.62
EV to EBITDA
27.83
EV to Capital Employed
2.28
EV to Sales
4.85
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.54%
ROE (Latest)
3.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
112.00
116.00
-3.45%
Operating Profit (PBDIT) excl Other Income
0.00
33.00
-100.00%
Interest
0.00
0.70
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10.50
16.20
-35.19%
Operating Profit Margin (Excl OI)
0.00%
173.80%
-17.38%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -3.45% vs 6.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -35.19% vs 1.25% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
395.70
389.60
1.57%
Operating Profit (PBDIT) excl Other Income
98.20
100.60
-2.39%
Interest
3.00
2.80
7.14%
Exceptional Items
-1.10
0.40
-375.00%
Consolidate Net Profit
36.80
47.30
-22.20%
Operating Profit Margin (Excl OI)
111.20%
136.80%
-2.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.57% vs 22.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -22.20% vs 13.43% in Dec 2023
About HOB Biotech Group Corp. Ltd. 
HOB Biotech Group Corp. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






